Ephrin receptor

Choose Selective Ephrin receptor Inhibitors

Ephrin receptor Signaling Pathway Map

Ephrin receptor Signaling Pathways

Ephrin receptor Products

  • All (4)
  • Ephrin receptor Inhibitors (4)
  • New Ephrin receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S0256 Ehp-inhibitor-1 Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors.
S2202 NVP-BHG712 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
Cell Rep, 2021, 35(1):108940
Mol Ther Nucleic Acids, 2021, 25:328-341
Cancer Lett, 2020, 475:53-64
S6515 ALW II-41-27 ALW II-41-27 (compound 7) is a potent inhibitor of Eph receptor tyrosine kinase with Kd of 12 nM for EphA2.
S8573 Sitravatinib (MGCD516) Sitravatinib (MGCD516, MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
Cancers (Basel), 2021, 13(21)5474
Cancers (Basel), 2020, 12(1)
S0256 Ehp-inhibitor-1 Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors.
S2202 NVP-BHG712 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
Cell Rep, 2021, 35(1):108940
Mol Ther Nucleic Acids, 2021, 25:328-341
Cancer Lett, 2020, 475:53-64
S6515 ALW II-41-27 ALW II-41-27 (compound 7) is a potent inhibitor of Eph receptor tyrosine kinase with Kd of 12 nM for EphA2.
S8573 Sitravatinib (MGCD516) Sitravatinib (MGCD516, MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
Cancers (Basel), 2021, 13(21)5474
Cancers (Basel), 2020, 12(1)